AI assistant
ANAPTYSBIO, INC — Director's Dealing 2017
Jan 26, 2017
32596_dirs_2017-01-25_eca62206-9b13-4679-879e-365d3a954a0e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2017-01-25
Reporting Person: Lydon Nicholas (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 67332 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series B Preferred Stock | $0.00 | Common Stock (80877) | Direct | ||
| Series C Preferred Stock | $0.00 | Common Stock (55403) | Direct | ||
| Series D Preferred Stock | $0.00 | Common Stock (67345) | Direct | ||
| Director Stock Option (right to buy) | $1.12 | 2021-12-08 | Common Stock (6828) | Direct | |
| Director Stock Option (right to buy) | $0.70 | 2024-07-10 | Common Stock (24184) | Direct | |
| Warrant to Purchase Series C Preferred Stock (right to buy) | $4.55 | 2018-11-04 | Series C Preferred Stock (16483) | Direct |
Footnotes
F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.
F2: The stock option is fully vested and immediately exercisable.
F3: The stock option vested and became exercisable as to 25% of the shares subject to the option on January 1, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
F4: This warrant is exercisable at any time.